SGLT2 inhibitors, initially developed for the management of type 2 diabetes mellitus, have shown remarkable benefits in heart failure management, particularly in patients with reduced ejection fraction (HFrEF), unlike traditional HF medications like beta-blockers and ACE inhibitors, which primarily target neurohormonal pathways, SGLT2 inhibitors work by a different mechanism [11]. The gene discussed is SLC5A2; the disease is heart failure.